Bailard, Inc. Abb Vie Inc. Transaction History

Bailard, Inc.

$3.8 Billion
Q3 2024

A detailed history of Bailard, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Bailard, Inc. holds 17,508 shares of ABBV stock, worth $3.15 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

17,508

Previous 17,488 0.11%

Holding current value

$3.15 Million

Previous $3 Million 15.27%

% of portfolio

0.09%

Previous 0.08%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 30, 2024	BUY	$163.84 - $199.33 $3,276 - $3,986	20 Added 0.11%	17,508 $3.46 Million
Q2 2024 Jul 25, 2024	SELL	$154.79 - $180.76 $507,246 - $592,350	-3,277 Reduced 15.78%	17,488 $3 Million
Q1 2024 May 08, 2024	SELL	$159.82 - $182.1 $26,530 - $30,228	-166 Reduced 0.79%	20,765 $3.78 Million
Q4 2023 Feb 02, 2024	SELL	$137.6 - $154.97 $25,043 - $28,204	-182 Reduced 0.86%	20,931 $3.24 Million
Q3 2023 Oct 24, 2023	SELL	$133.59 - $154.65 $11,755 - $13,609	-88 Reduced 0.42%	21,113 $3.15 Million
Q2 2023 Jul 20, 2023	SELL	$132.51 - $164.9 $894,707 - $1.11 Million	-6,752 Reduced 24.15%	21,201 $2.86 Million
Q1 2023 May 08, 2023	BUY	$144.61 - $166.54 $1,446 - $1,665	10 Added 0.04%	27,953 $4.45 Million
Q4 2022 Feb 02, 2023	SELL	$138.31 - $165.87 $7,192 - $8,625	-52 Reduced 0.19%	27,943 $4.52 Million
Q3 2022 Oct 18, 2022	SELL	$134.21 - $153.93 $8,723 - $10,005	-65 Reduced 0.23%	27,995 $3.76 Million
Q2 2022 Jul 27, 2022	SELL	$137.62 - $174.96 $27,524 - $34,992	-200 Reduced 0.71%	28,060 $4.3 Million
Q1 2022 Apr 25, 2022	SELL	$131.98 - $163.75 $103,736 - $128,707	-786 Reduced 2.71%	28,260 $4.58 Million
Q4 2021 Feb 10, 2022	BUY	$107.43 - $135.93 $85,944 - $108,744	800 Added 2.83%	29,046 $3.93 Million
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $4,788 - $5,435	45 Added 0.16%	28,246 $3.05 Million
Q2 2021 Aug 13, 2021	SELL	$105.21 - $117.21 $176,437 - $196,561	-1,677 Reduced 5.61%	28,201 $3.18 Million
Q1 2021 May 13, 2021	BUY	$102.3 - $112.62 $2.43 Million - $2.67 Million	23,715 Added 384.8%	29,878 $3.23 Million
Q4 2020 Feb 03, 2021	BUY	$80.49 - $108.67 $15,454 - $20,864	192 Added 3.22%	6,163 $660,000
Q3 2020 Nov 10, 2020	SELL	$85.91 - $100.83 $208,245 - $244,411	-2,424 Reduced 28.87%	5,971 $523,000
Q2 2020 Aug 12, 2020	BUY	$73.37 - $98.18 $58,549 - $78,347	798 Added 10.5%	8,395 $824,000
Q1 2020 Apr 16, 2020	BUY	$64.5 - $97.79 $92,041 - $139,546	1,427 Added 23.13%	7,597 $579,000
Q4 2019 Jan 31, 2020	SELL	$72.13 - $90.25 $131,565 - $164,616	-1,824 Reduced 22.82%	6,170 $546,000
Q3 2019 Oct 18, 2019	SELL	$62.98 - $75.72 $21,728 - $26,123	-345 Reduced 4.14%	7,994 $605,000
Q2 2019 Jul 26, 2019	SELL	$65.7 - $83.98 $15,505 - $19,819	-236 Reduced 2.75%	8,339 $606,000
Q1 2019 Apr 24, 2019	SELL	$77.14 - $90.79 $47,518 - $55,926	-616 Reduced 6.7%	8,575 $691,000
Q4 2018 Feb 05, 2019	BUY	$77.85 - $96.01 $94,432 - $116,460	1,213 Added 15.2%	9,191 $847,000
Q3 2018 Nov 13, 2018	BUY	$88.91 - $98.84 $76,729 - $85,298	863 Added 12.13%	7,978 $755,000
Q2 2018 Aug 08, 2018	SELL	$89.78 - $106.23 $369,444 - $437,136	-4,115 Reduced 36.64%	7,115 $659,000
Q1 2018 May 07, 2018	SELL	$92.01 - $123.21 $6,900 - $9,240	-75 Reduced 0.66%	11,230 $1.06 Million
Q4 2017 Feb 08, 2018	BUY	$89.56 - $98.21 $561,093 - $615,285	6,265 Added 124.31%	11,305 $0
Q2 2017 Aug 11, 2017	SELL	N/A	-1,437 Reduced 22.19%	5,040 $0
Q1 2017 Jan 29, 2018	BUY	N/A	1,031 Added 18.93%	6,477 $422,000
Q4 2016 Jan 29, 2018	SELL	N/A	-547 Reduced 9.13%	5,446 $0
Q3 2016 Jan 29, 2018	BUY	N/A	564 Added 10.39%	5,993 $378,000
Q2 2016 Jan 29, 2018	BUY	N/A	5,429	5,429 $0

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bailard, Inc. with notifications on news.

Account